B-cell therapy (rituximab) depletes circulating CD20+ B cells in cerebrospinal fluid, but their specific effects in RRMS remain limited.<h4>Objective</h4>The aim of the present study was to evaluate the effect of DMDs such as IFN-b-1A, fingolimod and rituximab on neurofilament light chain (NFL) and chitinase 3-like 1 (CHI3L1) serum levels, and some biomarkers of plasmacytoid dendritic cells (pDCs) in RRMS patients.<h4>Methods</h4>Thirty healthy controls and 44 RRMS patients actively receiving their DMDs, were recruited into this study. Here, NEFL is linked to relapsing-remitting multiple sclerosis.